Oncolytic adenovirus encoding a TGF-β inhibitor synergizes with PD-1 blockade to potentiate NK cell cytotoxicity against NSCLC
Our findings suggest that the combination of a PD-1 antibody, NK cells, and the oncolytic adenovirus Ad-anti-TGF-βRII represents a promising therapeutic strategy for NSCLC by remodeling the tumor microenvironment (TME) to overcome ICI resistance.
Authors
- Yan Zhang (ORCID: https://orcid.org/0000-0001-5738-9537)
- Xiaoli Kong (ORCID: https://orcid.org/0009-0001-5175-8685)
- Chonghe Xu
- Qingmei Zhang (ORCID: https://orcid.org/0000-0002-0348-0869)
- Mei Zhu (ORCID: https://orcid.org/0000-0003-3625-8794)
- Zhongqi Zhu
- Wei Xu
- Shuo Zhang
- Shuping Lu
Institutions
- Capital Medical University (CN)
- Anhui Medical University (CN)
- Chaohu Hospital of Anhui Medical University (CN)
- Beijing Anzhen Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Fourth Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-25
- DOI
- https://doi.org/10.3389/fimmu.2026.1759236
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00